MCID: HPT073
MIFTS: 73

Hepatitis C Virus malady

Categories: Genetic diseases, Rare diseases, Liver diseases, Gastrointestinal diseases, Immune diseases, Skin diseases, Infectious diseases

Aliases & Classifications for Hepatitis C Virus

Aliases & Descriptions for Hepatitis C Virus:

Name: Hepatitis C Virus 54
Hepatitis C Virus Infection, Response to Therapy of 54 24 29
Hepatitis C Virus, Susceptibility to 54 29
Response to Antiviral Treatment in Hepatitis C 56
Hepatitis C Virus, Response to Therapy of 54
Response to Peg/ifn-Ribavirin in Hcv 56
Hepatitic C Virus, Susceptibility to 13
Hepatitic C Virus 54

Classifications:



External Ids:

OMIM 54 609532
Orphanet 56 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 54 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute... (609532) more...

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus infection, response to therapy of, is related to recurrent hepatitis c virus induced liver disease in liver transplant recipients and hepatitis c. An important gene associated with Hepatitis C Virus is IFNL3 (Interferon Lambda 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Cyclosporine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and b cells, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
id Related Disease Score Top Affiliating Genes
1 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.1
2 hepatitis c 11.9
3 hepatocellular carcinoma 11.5
4 hepatitis 11.3
5 ifnl3-related altered drug metabolism 11.0
6 immunotactoid glomerulopathy 10.9
7 immunotactoid or fibrillary glomerulopathy 10.9
8 fibrillary glomerulonephritis 10.9
9 cryoglobulinemia 10.7
10 liver disease 10.5
11 glomerulonephritis 10.5
12 hepatitis b 10.4
13 lymphoma 10.4
14 hereditary alpha tryptasemia syndrome 10.4 GPT HLA-DRB1 IFNG
15 benign deep fibrous histiocytoma 10.4 GPT HLA-DRB1 IFNG
16 hyperimmunoglobulin syndrome 10.4 CLEC4M IFNG IRF3
17 membranoproliferative glomerulonephritis 10.4
18 porphyria cutanea tarda 10.4
19 porphyria 10.4
20 hereditary spastic paraplegia 10.3 DDX3X GPT IFNG PSMA7
21 bacterial meningitis 10.3 CLDN1 GPT HLA-DRB1
22 caplan's syndrome 10.3 HLA-DRB1 IFNG
23 hereditary hemorrhagic telangiectasia 10.3 CD81 CLDN1 DDX58 GPT IFNL4 IRF3
24 vasculitis 10.3
25 liver cirrhosis 10.3
26 eczematous dermatitis of eyelid 10.3 CD81 CLDN1 CLEC4M DDX58 GPT HLA-DRB1
27 lichen planus 10.2
28 distal trisomy 14q 10.2 HLA-DRB1 IFNG
29 oral lichen planus 10.2
30 b-cell lymphomas 10.1
31 type ii mixed cryoglobulinemia 10.1
32 arthritis 10.1
33 plantar fasciitis 10.1 CCR5 CLEC4M DDX58 IRF3
34 thyroiditis 10.0
35 leukemia 10.0
36 exophthalmos 10.0 CCR5 CD81 CLEC4M DDX58 GPT IFNG
37 thalassemia 10.0
38 kidney disease 10.0
39 hepatitis d 10.0
40 alcoholic hepatitis 10.0
41 thrombocytopenia 10.0
42 hemophilia 10.0
43 viral hepatitis 10.0
44 primary effusion lymphoma 10.0
45 hemochromatosis 10.0
46 hepatitis a 10.0
47 intrahepatic cholangiocarcinoma 10.0
48 hiv-1 10.0
49 nonalcoholic steatohepatitis 10.0
50 polyneuropathy 9.9

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.76 CD81 CLDN1 DDX3X GPT HM13 IRF3
2 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after direct virus infection GR00233-A-2 9.26 CLDN1 DDX3X IRF3 PI4KA
3 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection GR00233-A-3 8.92 CLDN1 DDX3X IRF3 PI4KA

MGI Mouse Phenotypes related to Hepatitis C Virus:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR5 CD81 CLEC4M DDX58 GPT HM13
2 immune system MP:0005387 9.36 IFNL3 IRF3 PI4KA PTPRC SCARB1 CCR5

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 606)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
4
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
5
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
7
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
8
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3 6493-05-6 4740
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
11
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
12
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
13
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
14
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
15
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
16
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
17
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
18
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
19
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
20
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
21
Insulin Glargine Approved Phase 4 160337-95-1
22
Insulin-glulisine Approved Phase 4 207748-29-6
23
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
24
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
25
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
26
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
27
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2 3424-98-4 159269
28
Isoniazid Approved Phase 4,Phase 2,Phase 3 54-85-3 3767
29
Pyrazinamide Approved Phase 4 98-96-4 1046
30
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
31
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
32
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
33
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
34
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1 1256388-51-8 67505836
35
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1190307-88-0 45375808
36
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
37
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
38
Interferon alfacon-1 Approved Phase 4,Phase 3,Phase 2 118390-30-0 9554198
39
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 1 376348-65-1 3002977
40
Lopinavir Approved Phase 4,Phase 3,Phase 2,Phase 1 192725-17-0 92727
41
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
42
Rifaximin Approved, Investigational Phase 4,Phase 2 80621-81-4 6436173
43
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
44
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
45
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
46
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
47
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
48
Cobicistat Approved Phase 4,Phase 3,Phase 1 1004316-88-4
49
Daclizumab Approved, Investigational Phase 4 152923-56-3
50
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925

Interventional clinical trials:

(show top 50) (show all 2333)
id Name Status NCT ID Phase
1 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4
2 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
3 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4
4 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
5 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4
6 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4
7 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4
8 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4
9 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4
10 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
11 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4
12 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4
13 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4
14 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4
15 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
16 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
17 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
18 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4
19 Ribavirin, Its Dosing Regime Unknown status NCT00484328 Phase 4
20 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4
21 Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients Unknown status NCT00526448 Phase 4
22 36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8 Unknown status NCT01683786 Phase 4
23 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4
24 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
25 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
26 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4
27 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
28 Hemostasis in Kocher-Langenbeck Approaches for Acetabular Surgery Using a Topical Surgical Hemostat (Vitagel) Unknown status NCT01230931 Phase 4
29 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
30 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
31 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4
32 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
33 Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients Completed NCT01469884 Phase 4
34 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4
35 Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 Completed NCT00143000 Phase 4
36 Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation Completed NCT00821587 Phase 4
37 A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir Completed NCT02103699 Phase 4
38 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4
39 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4
40 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4
41 Australian Trial in Acute Hepatitis C Completed NCT00192569 Phase 4
42 Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Completed NCT00938860 Phase 4
43 Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation. Completed NCT00383864 Phase 4
44 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. Completed NCT00545233 Phase 4
45 Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C) Completed NCT02768961 Phase 4
46 Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users Completed NCT00194480 Phase 4
47 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4
48 PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C. Completed NCT00087633 Phase 4
49 The SIM-SOF Trial for Hepatitis C Completed NCT02168361 Phase 4
50 Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy Completed NCT01120795 Phase 4

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

id Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 29
2 Hepatitis C Virus Infection, Response to Therapy of 29 24 IFNL3

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

39
Liver, T Cells, B Cells, Testes, Kidney, Bone, Monocytes

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 3546)
id Title Authors Year
1
Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. ( 28088461 )
2017
2
A preliminary investigation on single nucleotide polymorphism rs2287622 of bile salt export pump gene in patients with chronic hepatitis C virus infection in Hunan, China. ( 28292275 )
2017
3
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. ( 28535298 )
2017
4
Direct-acting antivirals for hepatitis C virus induce a rapid clinical and biochemical remission of porphyria cutanea tarda. ( 28369802 )
2017
5
Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations. ( 28512229 )
2017
6
Hepatitis C virus lipoviroparticles (HCV-LVP) assemble in the endoplasmic reticulum (ER) and bud off from the ER to Golgi in COPII vesicles. ( 28515296 )
2017
7
Single nucleotide polymorphisms of interleukins associated with hepatitis C virus infection in Egypt. ( 28368861 )
2017
8
Clinical development of hepatitis C virus host-targeting agents. ( 28087068 )
2017
9
Genome-wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection. ( 28065765 )
2017
10
Overall Structural Model of NS5A Protein from Hepatitis C Virus and Modulation by Mutations Confering Resistance of Virus Replication to Cyclosporin A. ( 28535337 )
2017
11
JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. ( 28527663 )
2017
12
The second-generation of highly potent hepatitis C virus (HCV) NS3/4A protease inhibitors: Evolutionary design based on tailor-made amino acids, synthesis and major features of bio-activity. ( 28530544 )
2017
13
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents. ( 28529212 )
2017
14
Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults. ( 28081037 )
2017
15
Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. ( 28512226 )
2017
16
Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. ( 28529936 )
2017
17
Hepatitis C virus triggers Golgi fragmentation and autophagy through the immunity-related GTPase M. ( 28389568 )
2017
18
Development of proteinuria and focal segmental glomerulosclerosis during direct acting antiviral therapy for hepatitis C virus infection (HEP-16-2474.R1). ( 28211090 )
2017
19
Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain. ( 28521955 )
2017
20
Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection. ( 28127569 )
2017
21
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. ( 28089092 )
2017
22
Retinoid BMS411 (4-{[(5,5-dimethyl-8-phenyl-5,6-dihydronaphthalen-2-yl) carbonyl] amino} benzoic acid), a potential inhibitor of NS5A protein of hepatitis C virus, a candidate for combined therapy of hepatitis C infection. ( 28523927 )
2017
23
Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. ( 28514954 )
2017
24
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus. ( 28530647 )
2017
25
Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. ( 28516201 )
2017
26
Spontaneous clearance of chronic hepatitis C virus infection in HIV-positive patients, southeastern France. ( 28526244 )
2017
27
Hepatitis C virus alters metabolism of biogenic polyamines by affecting expression of key enzymes of their metabolism. ( 28082202 )
2017
28
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. ( 28521211 )
2017
29
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. ( 28083718 )
2017
30
Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients. ( 28533673 )
2017
31
Five Near full-length Hepatitis C virus sequences were isolated from HIV coinfected IDUs of China. ( 28075146 )
2017
32
Highly Successful Hepatitis C Virus (HCV) Treatment Outcomes in Human Immunodeficiency Virus/HCV-Coinfected Patients at a Large, Urban, Ryan White Clinic. ( 28534036 )
2017
33
Immune modulation by the Hepatitis C virus core protein. ( 28092420 )
2017
34
Genotype 3 Infection: The Last Stand of Hepatitis C Virus. ( 28074358 )
2017
35
Exosome mediated intercellular communication between hepatitis C virus infected hepatocytes and hepatic stellate cells. ( 28077652 )
2017
36
ADVANCES WITH USING CRISPR/CAS-MEDIATED GENE EDITING TO TREAT INFECTIONS WITH HEPATITIS B VIRUS AND HEPATITIS C VIRUS. ( 28087399 )
2017
37
Comparison of Abbott RealTime genotype II, GeneMatrix restriction fragment mass polymorphism, and Sysmex HISCL HCV Gr assays for hepatitis C virus genotyping. ( 28076298 )
2017
38
Primary Care Perspectives on Hepatitis C Virus Screening, Diagnosis and Linking Patients to Appropriate Care. ( 28087291 )
2017
39
Cooperative enhancement of translation by two adjacent microRNA-122/Argonaute 2 complexes binding to the 5' untranslated region of hepatitis C virus RNA. ( 28008821 )
2017
40
Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study. ( 28090038 )
2017
41
Prevalence and correlates of hepatitis C virus-associated inflammatory arthritis in a population-based cohort. ( 28532574 )
2017
42
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. ( 28512091 )
2017
43
Differential hepatitis C virus RNA target site selection and host factor activities of naturally occurring miR-122 3' variants. ( 28082397 )
2017
44
Characterization of HCV envelope diversification from acute to chronic infection using SMRT sequencing within a sexually-transmitted hepatitis C virus cluster. ( 28077634 )
2017
45
NS5B Promotes Degradation of the NORE1A Tumor Suppressor to Facilitate Hepatitis C Virus Replication. ( 28090674 )
2017
46
Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. ( 27652130 )
2016
47
Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus. ( 27649152 )
2016
48
Seronegative and occult hepatitis C virus infections in patients with hematological disorders. ( 27665588 )
2016
49
Hepatitis C virus and its protein NS4B activate the cancer-related STAT3 pathway via the endoplasmic reticulum overload response. ( 27180099 )
2016
50
Long non-coding RNA GAS5 inhibited hepatitis C virus replication by binding viral NS3 protein. ( 26945984 )
2016

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PTPRC PTPRC, 77C-G single nucleotide variant risk factor

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 CCR5 DDX58 HLA-DRB1 IFNG IFNL3 IRF3
2
Show member pathways
12.46 CLEC4M DDX58 HLA-DRB1 IFNG IRF3
3
Show member pathways
12.36 DDX3X DDX58 IFNG IFNL3 IRF3
4 12.27 DDX58 IFNG IRF3 PTPRC
5
Show member pathways
12.25 DDX58 HLA-DRB1 IFNG IRF3
6 11.87 DDX58 HLA-DRB1 IFNG IRF3
7
Show member pathways
11.66 CCR5 HLA-DRB1 IFNG
8 11.62 CLDN1 CLDN6 HLA-DRB1 PTPRC
9 11.22 CD81 CLDN1 CLDN6 DDX58 IRF3 SCARB1
10
Show member pathways
10.49 DDX58 IFNL3 IRF3

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 CCR5 HLA-DRB1 HM13 PTPRC SCARB1
2 bicellular tight junction GO:0005923 9.33 CLDN1 CLDN6 DDX58
3 Golgi-associated vesicle membrane GO:0030660 9.26 HM13 PI4KA
4 external side of plasma membrane GO:0009897 8.92 CCR5 HLA-DRB1 IFNG PTPRC

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.89 CLEC4M DDX3X DDX58 HLA-DRB1 IRF3
2 cell surface receptor signaling pathway GO:0007166 9.83 CCR5 CD81 IFNG PTPRC
3 innate immune response GO:0045087 9.8 CLEC4M DDX3X DDX58 IFNL3 IFNL4 IRF3
4 cellular response to lipopolysaccharide GO:0071222 9.73 CCR5 IFNG IRF3
5 response to virus GO:0009615 9.71 DDX3X DDX58 IFNG
6 T cell receptor signaling pathway GO:0050852 9.67 HLA-DRB1 IFNG PSMA7 PTPRC
7 defense response to virus GO:0051607 9.63 DDX58 IFNG IFNL3 IFNL4 IRF3 PTPRC
8 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-DRB1 IFNG IRF3
9 antigen processing and presentation GO:0019882 9.58 CLEC4M HLA-DRB1 IFNG
10 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.55 CLDN1 CLDN6
11 positive regulation of interferon-alpha production GO:0032727 9.51 DDX58 IRF3
12 positive regulation of immune response GO:0050778 9.48 IFNL3 IFNL4
13 regulation of T cell activation GO:0050863 9.46 IFNL3 IFNL4
14 positive regulation of interferon-beta production GO:0032728 9.43 DDX3X DDX58 IRF3
15 viral entry into host cell GO:0046718 9.43 CD81 CLDN1 CLDN6 CLEC4M HLA-DRB1 SCARB1
16 viral process GO:0016032 9.4 CCR5 CD81 CLDN1 CLDN6 CLEC4M DDX3X

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.17 CCR5 CD81 CLDN1 CLDN6 CLEC4M HLA-DRB1
2 MHC class II protein complex binding GO:0023026 8.96 CD81 HLA-DRB1

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....